ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Mar 03, 2017 15:00 JST
Source:
Novotech Health Holdings Pte Ltd
New Frost & Sullivan research reveals Asia as Preferred Destination for Clinical Trials
Sydney, Aus, Mar 03, 2017 - (ACN Newswire) - Frost & Sullivan released its latest white paper, 'Asia: Preferred Destination for Clinical Trials', with Asia Pacific specialist CRO Novotech. Research from the new white paper revealed Asia is quickly becoming a clinical research powerhouse; facilitated by the availability of vast treatment-naive patient pools, exceptional clinical infrastructure and talent, and low operational costs.
Commenting on the white paper, Novotech CEO Dr. John Moller said "Asia is an increasingly attractive destination for our biotech clients. The huge patient pools available in Asia are mainly concentrated in easily accessible urban areas, meaning that trials tend to recruit faster. In addition, the cost of trials in most Asian countries is significantly lower than the West."
"Now is an exciting time for clinical trials taking place in Asia. There are a number of large, state-of-the-art clinical trial centers in Asia that meet patient enrolment and retention goals, generate high-quality data, and are led by globally recognised key opinion leaders. Regulatory processes in Asia are continuing to become more streamlined. Novotech is actively working with a number of regulatory authorities and clinical trial centres to improve approval processes and timelines," said Dr. Moller.
Novotech presented the white paper to an audience of senior biotechnology and pharmaceutical executives in a private event at Outsourcing Clinical Trials - West Coast 2017, held in Burlingame, California (USA).
The new Frost & Sullivan white paper, 'Asia: Preferred Destination for Clinical Trials', is available as Executive Summary (
http://bit.ly/2lkrhAB
) or Full Paper (
http://bit.ly/2mkqHmn
).
About Novotech
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management.
Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners. For more information, please visit www.novotech-cro.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the Global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? www.frost.com.
Please contact:
Susan Fitzpatrick-Napier
Digital Mantra Group
T: +61 2 8218 2144 / +1 650 798 5238
E:
susan@dmgpr.com
W: www.digitalmantragroup.com
Source: Novotech Health Holdings Pte Ltd
Sectors: Daily News, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
More Latest Release >>
Related Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
More Press release >>